Document Detail

Effects of indomethacin, luteinizing hormone (LH), prostaglandin E2 (PGE2), trilostane, mifepristone, ethamoxytriphetol (MER-25) on secretion of prostaglandin E (PGE), prostaglandin F2alpha (PGF2alpha) and progesterone by ovine corpora lutea of pregnancy or the estrous cycle.
MedLine Citation:
PMID:  11305696     Owner:  NLM     Status:  MEDLINE    
Two experiments were conducted to determine the luteotropin of pregnancy in sheep and to examine autocrine and paracrine roles of progesterone and estradiol-17 beta on progesterone secretion by the ovine corpus luteum (CL). Secretion of progesterone per unit mass by day-8 or day-11 CL of the estrous cycle was similar to day-90 CL of pregnancy (P > or = 0.05). In experiment 1, secretion of progesterone in vitro by slices of CL from ewes on day-8 of the estrous cycle was increased (P < or = 0.05) by LH or PGE2. Secretion of progesterone in vitro by CL slices from day-90 pregnant ewes was not affected by LH (P > or = 0.05) while PGE2 increased (P < or = 0.05) secretion of progesterone. Day 8 ovine CL of the estrous cycle did not secrete (P > or = 0.05) detectable quantities of PGF2alpha or PGE while day-90 ovine CL of pregnancy secreted PGE (P < or = 0.05) but not PGF2alpha. Secretion of progesterone and PGE in vitro by day-90 CL of pregnancy was decreased (P < or = 0.05) by indomethacin. The addition of PGE2, but not LH, in combination with indomethacin overcame the decreases in progesterone by indomethacin (P < or = 0.05). In experiment 2, secretion of progesterone in vitro by day-11 CL of the estrous cycle was increased at 4-h (P < or = 0.05) in the absence of treatments. Both day-11 CL of the estrous cycle and day-90 CL of pregnancy secreted detectable quantities of PGE and PGF2alpha (P < or = 0.05). In experiment 1, PGF2alpha secretion by day-8 CL of the estrous cycle and day-90 ovine CL of pregnancy was undetectable, but was detectable in experiment 2 by day-90 CL. Day 90 ovine CL of pregnancy also secreted more PGE than day-11 CL of the estrous cycle (P < or = 0.05), whereas day-8 CL of the estrous cycle did not secrete detectable quantities of PGE (P > or = 0.05). Trilostane, mifepristone, or MER-25 did not affect secretion of progesterone, PGE, or PGF2alpha by day- 11 CL of the estrous cycle or day-90 CL of pregnancy (P > or = 0.05). It is concluded that PGE2, not LH, is the luteotropin at day-90 of pregnancy in sheep and that progesterone does not modify the response to luteotropins. Thus, we found no evidence for an autocrine or paracrine role for progesterone or estradiol-17 36 on luteal secretion of progesterone, PGE or PGF2alpha.
L Kim; Y S Weems; P J Bridges; B R LeaMaster; L Ching; D L Vincent; C W Weems
Related Documents :
21425196 - Hemodynamics of fetal breathing movements: the inferior vena cava.
22986096 - Syncytiotrophoblast-derived microparticle shedding in early-onset and late-onset severe...
21382466 - Intrauterine inflammation, insufficient to induce parturition, still evokes fetal and n...
12009386 - Progesterone receptor localization and isoforms in myometrium, decidua, and fetal membr...
2361476 - The molecular weight profile of enkephalin-containing peptides in the sheep adrenal gla...
21207386 - Incremental cost of non-invasive prenatal diagnosis versus invasive prenatal diagnosis ...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Prostaglandins & other lipid mediators     Volume:  63     ISSN:  1098-8823     ISO Abbreviation:  Prostaglandins Other Lipid Mediat.     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-04-17     Completed Date:  2001-08-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9808648     Medline TA:  Prostaglandins Other Lipid Mediat     Country:  United States    
Other Details:
Languages:  eng     Pagination:  189-203     Citation Subset:  IM    
Dept. of Animal Science, University of Hawaii, Honolulu 96822, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3-Hydroxysteroid Dehydrogenases / antagonists & inhibitors
Corpus Luteum / drug effects,  secretion*
Cyclooxygenase Inhibitors / pharmacology
Dihydrotestosterone / analogs & derivatives,  pharmacology
Dinoprost / secretion*
Dinoprostone / pharmacology
Enzyme Inhibitors / pharmacology
Estradiol / physiology*
Estrogen Antagonists / pharmacology
Ethamoxytriphetol / pharmacology
Hormone Antagonists / pharmacology
Indomethacin / pharmacology
Luteinizing Hormone / pharmacology
Mifepristone / pharmacology
Progesterone / antagonists & inhibitors,  physiology*,  secretion*
Prostaglandins E / secretion*
Sheep / physiology*
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Enzyme Inhibitors; 0/Estrogen Antagonists; 0/Hormone Antagonists; 0/Prostaglandins E; 13647-35-3/trilostane; 363-24-6/Dinoprostone; 50-28-2/Estradiol; 521-18-6/Dihydrotestosterone; 53-86-1/Indomethacin; 551-11-1/Dinoprost; 57-83-0/Progesterone; 67-98-1/Ethamoxytriphetol; 84371-65-3/Mifepristone; 9002-67-9/Luteinizing Hormone; EC 1.1.-/3-Hydroxysteroid Dehydrogenases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Regulation of prostacyclin synthesis by angiotensin II and TNF-alpha in vascular smooth muscle.
Next Document:  Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown anx...